Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

0 avis

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

Archive ouverte

Edité par CCSD ; Elsevier -

International audience.

Introduction: Pralsetinib is a RET inhibitor found to have antitumor activity in advanced, metastatic, RET fusionpositive NSCLC.

Objective: To assess real-world efficacy of pralsetinib and treatment sequences in patients with RET fusion-positive NSCLC.

Design: Retrospective study of consecutive patients enrolled in the French expanded-access program for pralsetinib from December 1, 2019, to December 31, 2021.

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

Archive ouverte | Chour, Ali | CCSD

International audience

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. Efficacité des inhibiteurs de checkpoint immunitaire dans le carcinome sarcomatoïde du poumon : données issues d'une cohorte française multicentrique

Archive ouverte | Domblides, Charlotte | CCSD

National audience. Immune checkpoint inhibitors (ICIs) have improved cancer prognosis but have not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer subtype with poor prognosis. As such, ...

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation

Archive ouverte | Auliac, Jean Bernard | CCSD

International audience. Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in clinical trials. H...

Chargement des enrichissements...